HomeEXECUTIVESDavid J. Vigerust, MS., PhD Named Chief Scientific Officer of Spectrum Solutions

David J. Vigerust, MS., PhD Named Chief Scientific Officer of Spectrum Solutions

April 14, 2021

David J. Vigerust, MS, Ph.D. has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.

Much of Dr. Vigerust’s success is attributed to his superior logical and analytical approach in formulating innovative, non-linear industry solutions.

“Not only is Dr. Vigerust an award-winning and highly respected researcher and professor, he also has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science,” said Stephen Fanning, CEO of Spectrum Solutions.

In addition to his new role at Spectrum, Dr. Vigerust additionally holds teaching positions at Vanderbilt University Medical Center in the Department of Neurological Surgery as well as the University of Maryland, Eastern Shore School of Pharmacy. Throughout his career, he has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease and cancer.

Over the past 20 years he has been the recipient of many research awards and honors including his selection as the 2016 TEDx presenting industry expert and speaker on the subject of precision medicine.

Dr. Vigerust received a bachelor’s degree in biology and chemistry from the University of Texas at El Paso, a master’s degree in microbiology and immunology from Texas Tech University in Lubbock, and a Ph.D. in cellular and molecular pathology from Vanderbilt University in Nashville, TN. Dr. Vigerust conducted post-doctoral research on viral glycosylation, host defense from influenza, and bacterial secondary infection in the Department of Infectious Disease at St. Jude Children’s Research Hospital. He completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatric Infectious Disease in the area of molecular biology of respiratory viruses.

Dr. Vigerust has presented his research at national and international conferences and he is also an active editor and reviewer for several medical journals. He has been published in 26 peer-reviewed journals including Enhancement of Innate Immunity to COVID-19 with Natural Measures, published in Immunome Research in October 2020 and Microvascular disease confers additional risk to COVID-19 infection published in Medical Hypothesis in November, 2020.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


"We are excited to welcome Jeff Anderson to Nutjobs as our new CEO. His broad experience and tactical leadership will be instrumental in executing against our vision to provide innovative, sustainable solutions to our customers," said Paul Kephart, Co-Founder, Chief Technology Officer and Chairperson of the Nutjobs Board.
Potrero Medical believes that this voluntary reorganization will bolster its finances and facilitate its ongoing focus on elevating patient care.
Dr John Parker will work closely with PeriGen's client base to optimize use of the company's analytics for patient care and research. He will also be instrumental in informing product development and regulatory affairs as PeriGen continues to expand its product suite and associated services.
“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.
Broken String Biosciences reports Gavin Burns will be responsible for building and optimizing the companys teams, processes, and systems.

By using this website you agree to accept Medical Device News Magazine Privacy Policy